Superluminal secures $60M for Phase 1 of genetic obesity drug

A Boston biotech following in the footsteps of Rhythm Pharmaceuticals and others in the MC4R obesity field has raised $60 million to test its approach in Phase 1. Superluminal Medicines secured the Series B from ...